New agents and regimens for diffuse large B cell lymphoma

New agents and regimens for diffuse large B cell lymphoma

Abstract As a widely recognized standard regimen, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone) is able to cure two-thirds patients with diffuse large B cell lymphoma (DLBCL), and the remaining patients suffer from refractory or relapsed disease due to resistance...

Full description

Bibliographic Details
Main Authors:	Liang Wang, Lin-rong Li, Ken H. Young
Format:	Article
Language:	English
Published:	BMC 2020-12-01
Series:	Journal of Hematology & Oncology
Subjects:	Diffuse large B cell lymphoma Chimeric antigen receptor T cells Immunotherapy Chemoresistance Novel agents Genetic classification
Online Access:	https://doi.org/10.1186/s13045-020-01011-z

Similar Items

Severe early hepatitis B reactivation in a patient receiving anti-CD19 and anti-CD22 CAR T cells for the treatment of diffuse large B-cell lymphoma
by: Jia Wei, et al.
Published: (2019-11-01)

Regional Injection of CAR-T Cells for the Treatment of Refractory and Recurrent Diffuse Large B Cell Lymphoma: A Case Report
by: Yan-Hui Wei, et al.
Published: (2020-05-01)

Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy
by: Penny Q. Fang, et al.
Published: (2021-03-01)

Case Report: Combined Intravenous Infusion and Local Injection of CAR-T Cells Induced Remission in a Relapsed Diffuse Large B-Cell Lymphoma Patient
by: Linhui Hu, et al.
Published: (2021-04-01)

Challenges of driving CD30-directed CAR-T cells to the clinic
by: Natalie S. Grover, et al.
Published: (2019-03-01)

Composite lymphoma with coexistence of diffuse large B-cell lymphoma and anaplastic large cell lymphoma: Diagnostic pitfalls
by: Meyyappa Devan Rajagopal, et al.
Published: (2017-01-01)

TGF-β/IL-7 Chimeric Switch Receptor-Expressing CAR-T Cells Inhibit Recurrence of CD19-Positive B Cell Lymphoma
by: Kyung-Eun Noh, et al.
Published: (2021-08-01)

Anti-CD19 CAR T-cell therapy remission despite prior anti-CD19 antibody Tafasitamab in relapsed/refractory DLBCL
by: Nadeem Tabbara, et al.
Published: (2021-01-01)

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma
by: Sanfang Tu, et al.
Published: (2019-12-01)

The Great War of Today: Modifications of CAR-T Cells to Effectively Combat Malignancies
by: Andriy Zhylko, et al.
Published: (2020-07-01)

Newest Approaches in Immunotherapy for Non-Hodgkin’s Lymphoma
by: Emily C. Ayers, et al.
Published: (2018-12-01)

Memory stem T cells modified with a redesigned CD30‐chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma
by: Carmen Alvarez‐Fernández, et al.
Published: (2021-01-01)

miRNA signature associated with R–CHOP refractoriness in patients diagnosed with diffuse large B cell lymphoma
by: Oscar Raul Fajardo-Ramirez, et al.
Published: (2020-12-01)

Primary gastrointestinal diffuse large B-cell lymphoma: A prospective study from South India
by: Babu Suresh, et al.
Published: (2019-01-01)

Chimeric Antigen Receptors for T-Cell Malignancies
by: Lauren D. Scherer, et al.
Published: (2019-03-01)

Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
by: Shinichi Makita, et al.
Published: (2019-02-01)

Successful Chimeric Antigen Receptor (CAR) T-Cell Treatment in Aggressive Lymphoma Despite Coronavirus Disease 2019 (CoVID-19) and Prolonged Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Replication - Case Report
by: Verena Nilius-Eliliwi, et al.
Published: (2021-07-01)

Aberrant expression of multiple T cell markers on diffuse large B cell lymphoma: a case report
by: Anurag Mehta, et al.
Published: (2021-06-01)

Composite lymphoma of T-cell rich, histiocyte-rich diffuse large B-cell lymphoma and nodular lymphocyte predominant Hodgkin lymphoma: a case report
by: Asil Esper, et al.
Published: (2021-04-01)

Diffuse Large B Cell Lymphoma of the Breast
by: Feryal Karaca, et al.
Published: (2015-03-01)

CHOP VS. BOCAD in elderly patients with diffuse large cell lymphoma (DLCL): Preliminary results
by: Tomašević Zoran, et al.
Published: (2002-01-01)

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
by: Leonard Jeff Harris, et al.
Published: (2020-11-01)

Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial
by: Maria Castella, et al.
Published: (2020-03-01)

Redirecting T Cells against Epstein–Barr Virus Infection and Associated Oncogenesis
by: Christian Münz
Published: (2020-06-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

The efficacy of therapy with rituximab (R-CHOP) in patients with diffuse large cells lymphoma
by: T. D. Lutskaya, et al.
Published: (2014-07-01)

CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
by: YuanBo Xue, et al.
Published: (2021-02-01)

Safety and Efficacy of Anti-CD19-Chimeric Antigen Receptor T Cell Combined With Programmed Cell Death 1 Inhibitor Therapy in a Patient With Refractory Post-Transplant Lymphoproliferative Disease: Case Report and Literature Review
by: Gang Feng, et al.
Published: (2021-09-01)

FREQUENCY OF FEBRILE NEUTROPENIA IN ELDERLY PATIENTS OF DIFFUSE LARGE B CELL LYMPHOMA RECEIVING MODIFIED DOSE CHOP REGIMEN OF CHEMOTHERAPY
by: Tanvir Ahmed, et al.
Published: (2019-09-01)

The Multiple Faces of Genetically-Modified T Cells : Potential Applications in Therapy
by: Hillerdal, Victoria
Published: (2014)

Adult Ileocolic Intussusception Caused by Diffuse Large B Cell Lymphoma
by: Joon Woo Park, et al.
Published: (2020-01-01)

Primary diffuse large B-cell lymphoma of the ascending colon
by: Alan D. Gilman, et al.
Published: (2013-04-01)

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
by: Jun Meng, et al.
Published: (2021-10-01)

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
by: Jun Meng, et al.
Published: (2021-07-01)

Primary diffuse large B‐cell lymphoma of the bone mimicking osteomyelitis
by: Abbas Mofidi, et al.
Published: (2021-09-01)

Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors : From antigen choice to clinical implementation
by: Mohamed-Rachid Boulasse, et al.
Published: (2012-08-01)

Autologous Cytokine-Induced Killer Cell Immunotherapy for Patients with High-Risk Diffuse Large B Cell Lymphoma After the First Complete Remission
by: Zhou M, et al.
Published: (2020-06-01)

Intensive Debulking Chemotherapy Improves the Short-Term and Long-Term Efficacy of Anti-CD19-CAR-T in Refractory/Relapsed DLBCL With High Tumor Bulk
by: Cuicui Lyu, et al.
Published: (2021-07-01)

CAR-NK cells: A promising cellular immunotherapy for cancer
by: Guozhu Xie, et al.
Published: (2020-09-01)

You Have Got a Fast CAR: Chimeric Antigen Receptor NK Cells in Cancer Therapy
by: Aline Pfefferle, et al.
Published: (2020-03-01)